fbpx

Year

2020
Lundbeckfonden-forskere prøver med god folkeoplysning at få udbredt reel viden om migræne. Det er en kamp med udfordringer. Stakkels Maude, altså fru bankdirektør Hans Christian Varnæs i Matador, for hendes hverdag i Korsbæk var tit noget plaget. Og når livet gik hende mest imod, krøb hun i en årrække ofte til sengs. Der har været...
EO2401 combines three ‘OncoMimics’ designed to trigger the immune system into recognizing tumor cells as bacterial (i.e. non-self) and eliciting a targeted cell-killing response First patient dosed in Phase 1/2 (‘ROSALIE’) trial investigating EO2401 Paris, France and Cambridge, MA, USA – July 30, 2020 ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of...
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 27 July 2020: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), announces that the US Food and Drug Administration (FDA) has approved of a second supplier for...
Det er livsvigtigt, at immunsystemet træder i karakter, når kroppen angribes – fx af et sygdomsfremkaldende virus. Men hvis immunsystemet aktiveres for kraftigt, kan det give problemer. Netop den situation har 25 forskere fra Aarhus Universitet (AU) kigget nærmere på i en videnskabelig rapport, som de sammen med kolleger fra Norge, USA, Frankrig og Japan...
–    FDA has agreed to key aspects of the clinical program, including the primary endpoint for the single pivotal phase 3 study –    There are approximately 175,000 and 150,000 ESKD patients with PAD in the USA and Europe respectively with no approved treatments Palma, Spain and San Diego, USA, 20 July 2020 – Sanifit, a clinical-stage biopharmaceutical company developing...
Cambridge, UK and Indianapolis, US – 16 July 2020: Acacia Pharma Group plc (the “Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy, announces that application has been made to Euronext Brussels...
Acacia Pharma Assigned US License for BYFAVO™ (remimazolam) by Cosmo Pharmaceuticals NV This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 15 July 2020: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical...
Aarhus, Denmark, 14 July 2020 – NMD Pharma A/S, a biotech company leading in the development of novel therapeutics for neuromuscular disorders, today announces that it has received approval from the Dutch ethics committee and regulatory authorities to advance its development candidate, NMD670, into clinical trials as a novel treatment for the symptoms of myasthenia...
After Discussions with FDA, NDA Submission Planned for 3Q 2020 under Accelerated Approval Pathway  Reltecimod in conjunction with currently available standard of care demonstrated a significant difference in the percentage of patients who achieved resolution of organ dysfunction/failure by Day 14 versus standard of care alone  Resolution of organ dysfunction/failure at Day 14...
1 2 3 9

Nyheder

Urgammelt DNA kaster en ’videnskabelig håndgranat’ ind i diskussionen om menneskets ankomst til Amerika
23. juli 2020
Danske forskere kortlægger central sygdomsmekanisme – og beskriver et helt nyt protein
20. juli 2020
Fem unge medicinstuderende på forskningsophold i USA
9. juli 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge